Abstract: Pharmaceutical compositions and processes for their preparation containing R-&agr;-lipoic acid or S-&agr;-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Abstract: The present invention relates to salts of azelastine having improved solubility in water. The salts of the present invention are prepared by reacting azelastine with acetic acid, gluconic acid, lactic acid, or malic acid. The azelastine salts are effective in providing a cytoprotective effect.

Abstract: The present invention relates to salts of azelastine having improved solubility in water. The salts of the present invention are prepared by reacting azelastine with acetic acid, gluconic acid, lactic acid or malic acid. A pharmaceutical composition may be prepared containing an azelastine salt and a pharmaceutically-acceptable carrier or diluent therefor. The pharmaceutical composition is useful in the treatment of allergies, asthma, inflammatory and psoriasis disorders and provides a cytoprotective effect.

Abstract: Pharmaceutical compositions and processes for their preparation containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Abstract: Pharmaceutical compositions containing at least one compound of Formula I, ##STR1## where X is a hydrogen atom or both X's represent a direct link between the two sulphur atoms; Y is hydrogen or C.sub.1 -C.sub.6 alkyl and n represents a number from 1 to 10, or their pharmaceutically acceptable salts including .alpha.-lipoic acid and dihydrolipoic acid. The pharmaceutical compositions are useful for the treatment of diseases caused by retroviruses.

Abstract: The use of alkylphosphoric acid compounds of Formula IR--Y--PO.sub.2.sup..crclbar. --X--R.sub.1 Iwhere in Formula IR represents a saturated or unsaturated hydrocarbon radical with 12 to 24 carbon atoms or where R represents the group--CH.sub.2 --CHR.sub.3 --CH.sub.2 --Z--R.sub.4 and R.sub.3 is a C.sub.1 -C.sub.6 -alkoxy group or a C.sub.1 -C.sub.6 -alkoxymethyl group,Z represents oxygen or sulphur and R.sub.4 represents a C.sub.1 -C.sub.24 -alkyl radical,X is an oxygen atom, NH or NR.sub.2 and Y is an oxygen atom or NH, R.sub.1 is a C.sub.1 -C.sub.8 -alkyl group, or where R.sub.1 represents a C.sub.2 -C.sub.8 -alkyl group which is unsaturated and/or substituted by halogen, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, tri-C.sub.1 -C.sub.6 -alkylamino, hydroxy, carboxy, C.sub.3 -C.sub.8 -cycloalkyl or phenyl for the preparation of a pharmaceutical composition for combating psoriasis disorders.

Abstract: Azelastine-containing pharmaceutical compositions which provide controlled release of the active substance using a sustained release component. The compositions contain azelastine or a physiologically acceptable salt of azelastine, together with 0.001 to 800 parts of sustained release component for each part by weight of azelastine (calculated as base) and the release rate of azelastine is between 0.05 and 5 mg per hour.

Abstract: An embonic acid salt of azelastine is disclosed which does not possess the bitter taste of azelastine, and which therefore is suitable for orally administered formulations.

Abstract: Ifosfamide lyophilizate consisting substantially of ifosfamide and 0.1 to 17 parts by weight of a hexitol.

Abstract: Pharmaceutical compositions and their preparation which contain dihydrolipoic acid or its pharmaceutically acceptable salts as active substance. The pharmaceutical compositions have a cytoprotective effect and are suitable for combatting pain and inflammatory disorders.

Abstract: A medicine having a synergistic activity containing a combination of azelastine and theophylline or azelastine and at least one .beta.-mimetic.

Abstract: 1,2-Bis(aminomethyl)-cyclobutane-platinum complexes having an anti-tumor activity.

Abstract: There are disclosed compounds of the formula ##STR1## The compounds have antitumour and AIDS treatment activity.

Abstract: A compound of the general formula: ##STR1## wherein R.sub.1 is hydrogen, a hydroxy group or a C.sub.2 -C.sub.6 alkanoyloxy group, R.sub.2 is hydrogen or a halogen atom, R.sub.3 is hydrogen or a C.sub.1 -C.sub.6 alkyl group, R.sub.4 is a hydroxy group or a C.sub.2 -C.sub.6 alkanoyloxy group, R.sub.5 is hydrogen or a halogen atom and R.sub.6 is hydrogen or a halogen atom, Alk is a C.sub.2 -C.sub.10 alkylene chain where 4 neighboring CH.sub.2 groups may also be replaced by a 1,4-phenylene ring, A-B is the group HN--CH.sub.2 --CH.sub.2 --NH.sub.2, H.sub.2 N--CH.sub.2 --CH--CH.sub.2 --NH.sub.2 or ##STR2## and R.sub.7 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a phenyl radical and X stands for the equivalent of a physiologically acceptable anion. The compound is useful for the treatment of hormone dependent tumors.

Abstract: Solutions comprising oxazaphosphorins having the general formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are radicals and at least two of said radicals are 2-chloroethyl and/or 2-mathanesulfonyloxyethyl and the remaining radical is selected from hydrogen, methyl and ethyl; and about 80% to about 100% (v/v) ethanol; wherein the oxazaphosphorin concentration is about 10% to about 70% (w/v); and a process for the preparation thereof.

Abstract: Compounds of the general formula: ##STR1## wherein the radicals R.sub.1 and R.sub.2 are the same or different and represent hydrogen or C.sub.1 -C.sub.6 -alkyl, the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.2 -C.sub.6 -alkanoyloxy, halogen or C.sub.2 -C.sub.6 -alkanoyl, X is oxygen, sulphur or the group --NR.sub.5 and R.sub.5 is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkanoyl or benzoyl, m and n in each case may represent the integers 1, 2 or 3 and the phenyl radical A is unsubsituted or is substituted by halogen, nitro, C.sub.1 -C.sub.6 -alkyl, trifluoromethyl, C.sub.3 -C.sub.7 -cycloalkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.2 -C.sub.6 -alkanoyloxy, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, C.sub.2 -C.sub.6 -alkanoylamino, CN, carboxy, C.sub.1 -C.sub.6 -alkoxycarbonyl, phenyl, C.sub.1 -C.sub.

Abstract: Anti-asthmatically acting compounds of formula ##STR1## wherein R.sub.1 and R.sub.2 represent hydrogen, fluorine, chlorine, bromine, trifluoromethyl, C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -alkoxy and the radical A is the group ##STR2## wherein R.sub.3 is hydrogen, a phenyl radical, an indolyl-(3)-methyl radical, imidazolyl-(4)-methyl radical, a C.sub.1 -C.sub.10 -alkyl group or wherein R.sub.3 represents a C.sub.1 -C.sub.10 -alkyl group which is substituted by a carboxy group, a C.sub.1 -C.sub.6 -alkoxycarbonyl group, an aminocarbonyl group, a hydroxy group, a C.sub.1 -C.sub.6 -alkoxy group, a C.sub.2 -C.sub.6 -alkanoyl-oxy group, a mercapto group, a C.sub.1 -C.sub.6 -alkylthio group, a C.sub.2 -C.sub.6 -alkanoylmercapto group, a phenyl group, a hydroxyphenyl group, a dihydroxyphenyl group, an amino-C.sub.1 -C.sub.6 -alkylthio group, an amino-C.sub.1 -C.sub.6 -alkyloxy group, an amino group, a ureido group (H.sub.2 NCONH--) or a guanidino group or wherein R.sub.

Abstract: 2,6-diamino-3-halobenzylpyridines of the formula I: ##STR1## wherein R.sub.1 is fluorine and R.sub.2 is hydrogen or chlorine as well as their physiologically acceptable acid addition salts, processes for their manufacture and their use in pharmaceuticals.

Abstract: Through the combined use of a 4-sulfido-oxazaphosphorine of the formula: ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are hydrogen, methyl, ethyl, 2-chloroethyl or 2-methanesulfonyloxyethyl and at least two of them are taken from the group consisting of 2-chloroethyl and 2-methanesulfonyloxyethyl, R.sub.4 is hydrogen or methyl, R.sub.5 is a C.sub.2 -C.sub.6 -hydroxyalkyl group or a C.sub.2 -C.sub.6 -mercaptoalkyl group of each of these groups with an additional mercapto group, or R.sub.5 is a carboxy-C.sub.1 -C.sub.10 alkyl group, a carb-C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.10 -alkyl group, a 2-amino-2-carboxyethyl group, a 2-amine-2-carb-C.sub.1 -C.sub.6 -alkoxy-ethyl group, a 2-C.sub.2 -C.sub.6 -alkanoylamino-2-carboxyethyl group, the glutathionyl group, a C.sub.2 -C.sub.6 -sulfoalkyl group or a C.sub.2 -C.sub.6 -sulfoalkyl group which contains a mercapto group or a physiologically compatible salt thereof in combination with a thion compound of the formula:R.sub.6 SR.sub.7 IIwhere R.sub.